Core Viewpoint - Labcorp Holdings Inc. will release its financial results for Q4 2025 on February 17, 2026, before market opening, followed by a conference call at 9 a.m. ET to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for Q4 2025 will be released before the market opens on February 17, 2026 [1]. - A conference call and webcast will take place at 9 a.m. ET on the same day to discuss the financial results [1]. Group 2: Webcast and Participation - The conference call will be available via live webcast on the Labcorp Investor Relations website, with participants encouraged to join 10 minutes early [2]. - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until February 4, 2027 [3]. Group 3: Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4]. - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4]. - Labcorp conducts more than 700 million tests annually for patients worldwide [4].

Core Insights - 2025 was a significant year for LabCorp, focusing on four core therapeutic areas: oncology, women's health, autoimmune, and neurology [2] - The company launched over 100 tests in 2025, with the majority targeting the identified therapeutic areas, which are expected to grow 2 to 3 times faster than the overall diagnostic market [2] Strategic Focus - LabCorp's strategic focus on specific therapeutic areas is aimed at capitalizing on growth opportunities within the diagnostic market [2] - The anticipated growth rate of 2 to 3 times faster than the rest of the market indicates a strong potential for revenue increase in these segments [2]

Labcorp FY Conference Summary Company Overview - **Company**: Labcorp (NYSE: LH) - **Date of Conference**: January 13, 2026 Key Industry Insights - **Core Therapeutic Areas**: Labcorp is focusing on four core therapeutic areas: oncology, women's health, autoimmune, and neurology, which are expected to grow two to three times faster than the overall diagnostic market [5][6] - **M&A Activity**: In 2025, Labcorp announced 13 new or closed deals, enhancing growth opportunities [5] - **AI Integration**: Significant advancements in artificial intelligence and automation in laboratories, particularly in cytology and microbiology, were highlighted [6][32] Financial Performance - **2025 Performance**: Labcorp reported solid core fundamentals and improved organic growth, with a target of 4.5% organic revenue growth for the full year [13] - **Integration Success**: The integration of Invitae was noted as a remarkable achievement, turning a struggling company into an accretive business by Q3 2025 [7][10] - **Volume Impact from ACA Changes**: An estimated 30 basis points of volume impact on the diagnostic business in 2026 due to ACA subsidy expirations was discussed [20] Growth Drivers - **Increased Testing Utilization**: The aging population and a rise in chronic illnesses are driving increased testing utilization, which is expected to remain higher than pre-COVID levels [14][15] - **Specialty Testing Growth**: Labcorp anticipates growth in specialty testing, particularly in oncology, neurology, and autoimmune diseases, which are expected to drive higher test volumes [22][23] - **Managed Care Relationships**: Strong relationships with managed care organizations are expected to facilitate better pricing negotiations and increased volume [49] Challenges and Risks - **PAMA Legislation**: The potential impact of PAMA on pricing and diagnostics was discussed, with a cautious optimism regarding delays in its implementation [54][58] - **Biopharma Lab Services**: The early development segment is facing challenges due to funding and interest rates, leading to a focus on profitability and divestiture of non-core areas [64][65] Future Outlook - **Capital Deployment Strategy**: Labcorp plans to continue investing in capital expenditures, focusing on technology and infrastructure improvements [43][44] - **Tailwinds for 2026**: Anticipated strong underlying utilization trends, specialty testing growth, and M&A activities are expected to drive growth in 2026 [74] - **AI and Automation**: Continued focus on AI and automation is expected to enhance operational efficiency and reduce costs [73] Additional Insights - **Consumer Health Trends**: Increased consumer focus on health and wellness is seen as an opportunity for Labcorp's OnDemand services, which offer a variety of tests [51][52] - **Companion Diagnostics**: The importance of companion diagnostics in personalized medicine is emphasized as a way to reduce healthcare costs and improve patient outcomes [30][31] This summary encapsulates the key points discussed during the Labcorp FY conference, highlighting the company's strategic focus, financial performance, growth drivers, challenges, and future outlook.

Core Insights - Labcorp has expanded its molecular residual disease (MRD) portfolio to enhance early detection of cancer recurrence, introducing Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome tests for specific cancer stages [1][7]. Group 1: MRD Testing and Cancer Recurrence - Cancer recurrence rates are significant, with approximately 35% of stage III colon cancer patients and 10% to 40% of stage I-III breast cancer patients experiencing recurrence post-treatment [2]. - MRD testing detects circulating tumor DNA (ctDNA) in the bloodstream, allowing for earlier detection of recurrence, potentially months before traditional imaging methods [3][8]. - The Labcorp Plasma Detect tests can detect ctDNA down to a limit of detection (LOD95) of 0.005%, enabling oncologists to tailor surveillance strategies for patients [3]. Group 2: Clinical Utility and Research - Labcorp's expanded portfolio supports personalized and proactive cancer care, providing clinicians with advanced tools for tracking molecular residual disease [4]. - Ongoing and completed clinical studies demonstrate the utility of Labcorp Plasma Detect in monitoring disease progression and predicting long-term outcomes [4]. - Recent peer-reviewed publications have highlighted the effectiveness of Labcorp Plasma Detect in patients with diffuse pleural mesothelioma and head and neck cancer, reinforcing the importance of MRD testing in personalized cancer care [4]. Group 3: Comprehensive Oncology Solutions - Labcorp's offerings span the entire cancer care continuum, from screening and diagnosis to therapy selection and monitoring [5]. - The company collaborates with oncologists, health systems, and biopharma companies to drive precision medicine and improve patient outcomes globally [5]. - Labcorp performs over 700 million tests annually and has supported more than 75% of new drugs approved by the FDA in 2024 [6].

Group 1 - Labcorp will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 4:30 p.m. PT [1] - A live audio webcast of the fireside chat will be available on the Company Investor Relations website and archived for replay [1] Group 2 - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health [2] - The company employs nearly 70,000 people and serves clients in approximately 100 countries [2] - Labcorp supported over 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually [2]

Core Insights - Hologic and Labcorp are established players in the MedTech sector, each with unique strengths and market capitalizations of $16.71 billion and $20.89 billion respectively [1] Group 1: Hologic - Hologic's largest revenue segment is Diagnostics, driven by the Molecular Diagnostics unit, particularly the BV, CV/TV assay, which has become a major contributor to U.S. performance [3] - The Panther Fusion add-on module is gaining traction, with features like Open Access functionality allowing labs to run their own tests, and new FDA and CE-IVDR-approved assays diversifying the testing menu [4] - Hologic's acquisition of Biotheranostics in 2021 accelerated its entry into oncology, while innovations in breast health, such as AI-powered mammography solutions, are gaining clinical momentum [5] - Gynesonics enhanced the GYN Surgical product lineup with the Sonata System technology, and international market share for Myosure is increasing, indicating unmet demand for minimally invasive options [6] Group 2: Labcorp - Labcorp is executing a solid strategy focused on partnerships with health systems and laboratories, enhancing its market presence and access to a broad test menu [7] - The company is experiencing strong growth in specialty areas like oncology, women's health, and neurology, driven by scientific advancements and innovation [8] - Notable capabilities include HRD testing, FDA-cleared blood-based tests for Alzheimer's, and the Labcorp Plasma Complete liquid biopsy test, contributing to its growth [9] - Labcorp is investing in digital and AI capabilities to improve operational efficiency and aims for annual savings of $100-$125 million under the LaunchPad initiative [11] Group 3: Performance and Valuation - Both companies have underperformed compared to the S&P 500 over the past 12 months, but Labcorp has shown better resilience [12] - Hologic has a forward one-year price-to-sales (P/S) ratio of 3.86, while Labcorp's is significantly lower at 1.43, indicating a more favorable valuation for Labcorp [13] - Analyst price targets suggest a 2.6% upside for Hologic, with an average target of $76.92, while Labcorp has a 19.3% upside potential with a target of $300.71 [15][18] Group 4: Conclusion - Both companies hold a Zacks Rank 3 (Hold), with Hologic's strengths in Diagnostics and Breast Health and Labcorp's focus on partnerships and high-growth areas positively impacting their performance [20] - Labcorp is positioned as the stronger investment option based on valuation, price performance, and analyst targets compared to Hologic [20]

Summary of Healthcare Services Conference Call Industry Overview - The conference call focused on the **Healthcare Services** industry, particularly the **Managed Care** sector and its outlook for 2026, highlighting potential margin improvements and policy clarity as positive factors for growth [4][10][11]. Key Points and Arguments Managed Care - **Earnings Recovery**: Most Managed Care Organizations (MCOs) are expected to reach trough earnings in 2026, with potential upward revisions thereafter. Medicare Advantage (MA) is anticipated to drive margin upside, while skepticism remains around Medicaid and ACA Exchanges until MCOs demonstrate margin improvements [5][12]. - **Enrollment Trends**: MCOs are targeting enrollment declines to improve margins, with companies like CVS, ELV, and UNH focusing on this strategy. Conversely, HUM is positioned for membership growth [12][52]. - **Regulatory Environment**: The 2026 midterms are expected to create gridlock, reducing the likelihood of major policy changes outside of CMS rulemaking, which could stabilize the operating environment for MCOs [5][12]. Pharmaceutical Distributors - **Strong Fundamentals**: The current strength in results for pharmaceutical distributors is attributed to stable generic pricing, MSO growth, and a robust specialty pipeline. Companies like McKesson (MCK) and Cencora (COR) are favored due to their strong specialty businesses [9][16]. - **M&A Activity**: Distributors led M&A activity in 2025, with expectations for continued integration and organic investment in MSO capabilities in 2026 [25]. Labs and Healthcare Facilities - **Demand Trends**: Labs are expected to see steady demand trends with a healthy backdrop in diagnostics. Regulatory uncertainties may impact pricing and mix development, but overall operating conditions are stable [9][12]. - **Facility Performance**: Healthcare facilities are positioned to benefit from favorable utilization trends, although policy uncertainty remains a concern for future earnings growth [12][16]. Additional Insights - **Investment Picks**: Top investment picks include UnitedHealth (UNH) and CVS Health (CVS) for their cleaner stories, while Cigna (CI) is seen as attractive but with more complexities [5][14][17]. - **Margin Pressures**: Medicaid remains a challenge, with companies like ELV and UNH guiding for margin pressure in 2026. Investment income is also expected to be a headwind for managed care [5][12]. - **Market Dynamics**: The ACA Exchanges are viewed as a swing factor for MCOs, with a wide range of outcomes expected due to potential shifts in market morbidity [12][43]. Conclusion The healthcare services industry is navigating a complex landscape with potential for margin recovery and growth driven by Medicare Advantage, while facing challenges in Medicaid and ACA Exchanges. The focus on regulatory clarity and strategic M&A activity will be crucial for companies as they prepare for 2026 and beyond.

Investors in Labcorp Holdings Inc. (LH) need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 20, 2026 $135 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could als ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor's nationwide expansion and broaden patient access to its immunotherapy-response diagnostics. Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 states, representing more than $100. ...

Core Insights - Labcorp Holdings Inc. is expanding its business in specialty testing areas, including oncology, women's health, autoimmune disease, and neurology, while strengthening its market presence through strategic relationships with health systems and laboratories [1][8] - The company has shown solid financial stability, with a market capitalization of $22.28 billion and an earnings yield of 6.1%, outperforming the industry average of 3.4% [2] - Despite a 16.8% stock rally over the past year, macroeconomic challenges and currency impacts pose risks to Labcorp's operations [2][10] Business Expansion - Labcorp is enhancing its oncology and genetic testing portfolio, including the launch of OmniSeq INSIGHT for ovarian tumors and the CE marking of PGDx elio tissue complete [3] - The company has expanded access to Invitae genetic tests and introduced new Alzheimer's tests, maintaining strong momentum in its Labcorp OnDemand channel [4] - Strategic acquisitions and partnerships have driven growth, with $268 million invested in the third quarter of 2025, contributing 2.2% to top-line growth [5][6] Financial Performance - As of the end of the third quarter of 2025, Labcorp reported cash and cash equivalents of $598.1 million, with long-term debt at $5.08 billion [9] - The company returned capital to shareholders through dividends of $59.9 million and stock buybacks of $25 million during the quarter [9] Market Challenges - Labcorp faces macroeconomic risks, including reduced demand for diagnostic testing due to global economic volatility and inflation, which affects profitability [10] - The company's significant exposure to international markets makes it vulnerable to currency fluctuations, particularly with the strengthening U.S. dollar [11] Earnings Estimates - The Zacks Consensus Estimate for Labcorp's 2025 earnings has increased to $16.33, with revenues projected at $13.99 billion, indicating a 7.6% improvement from 2024 [12]